Condition: Healthy Person · Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
This study is a Phase I clinical trial that uses positive glucose clamping technology to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence of IBI3035 with insulin injection (Awiqli?) after a single administration in healthy male subjects
This description comes directly from the study's public registry record.
Shanyu Xu · +86-0512-69566088 · shanyu.xu@innoventbio.com
Always discuss trial participation with your own doctor first.
| Bishan Hospital of Chongqing | Chongqing, Chongqing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07591519